Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor
Richard De Vuyst, Charissa W. Kam, Cameron J. McKinzie, Charles R. Esther
Abstract
The authors declare no conflict of interest. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Topics & Concepts
IvacaftorMedicineLung functionIntensive care medicineLungCystic fibrosisInternal medicineCystic fibrosis transmembrane conductance regulatorCystic Fibrosis Research AdvancesAsthma and respiratory diseasesRespiratory and Cough-Related Research